Now showing items 1-20 of 28

    • Adherence in the CAPRISA 004 tenofovir gel microbicide trial. 

      Mansoor, Leila Essop.; Abdool Karim, Quarraisha.; Yende-Zuma, Nonhlanhla.; MacQueen, Kathleen M.; Baxter, Cheryl.; Madlala, Bernadette T.; Grobler, Anneke.; Salim S. Abdool Karim, Salim Safurdeen. (Springer., 2014)
      High adherence is key to microbicide effectiveness. Here we provide a description of adherence interventions and the adherence rates achieved in the CAPRISA 004 Tenofovir Gel Trial. Adherence support for the before-and-after ...
    • Antibodies for HIV prevention in young women. 

      Abdool Karim, Salim Safurdeen.; Abdool Karim, Quarraisha.; Baxter, Cheryl. (Wolters Kluwer., 2015)
      Abstract available.
    • Antiretroviral therapy : challenges and options in South Africa. 

      Abdool Karim, Salim Safurdeen.; Abdool Karim, Quarraisha.; Baxter, Cheryl. (Elsevier., 2003-11-01)
      No abstract available.
    • Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial. 

      Mansoor, Leila E.; Abdool Karim, Quarraisha.; Mngadi, Kathryn T.; Dlamini, Sarah.; Montague, Carl.; Nkomonde, Nelisiwe.; Mvandaba, Nomzamo.; Baxter, Cheryl.; Gengiah, Tanuja N.; Samsunder, Natasha.; Dawood, Halima.; Grobler, Anna Christina.; Frohlich, Janet A.; Abdool Karim, Salim Safurdeen. (BioMed Central., 2014)
      Background: The Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 trial demonstrated a 39% reduction in HIV infection, with a 54% HIV reduction in women who used tenofovir gel consistently. A confirmatory ...
    • Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial. 

      Sibeko, Sengeziwe.; Baxter, Cheryl.; Abdool Karim, Quarraisha.; Abdool Karim, Salim Safurdeen.; Yende Zuma, Nonhlanhla. (Lippincott Williams & Wilkins., 2011)
      OBJECTIVE: Women who become pregnant during the conduct of biomedical human immunodeficiency virus prevention trials are taken off the study product for safety reasons. High pregnancy rates can compromise statistical ...
    • A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. 

      Gengiah, Tanuja N.; Baxter, Cheryl.; Mansoor, Leila E.; Kharsany, Ayesha B. M.; Abdool Karim, Salim Safurdeen. (Informa Healthcare., 2011)
      Introduction: More than a million people acquire HIV infection annually. Pre-exposure prophylaxis (PrEP) using antiretrovirals is currently being investigated for HIV prevention. Oral and topical formulations of tenofovir ...
    • Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. 

      Abdool Karim, Salim Safurdeen.; Abdool Karim, Quarraisha.; Frohlich, Janet A.; Grobler, Anna Christina.; Baxter, Cheryl.; Mansoor, Leila E.; Kharsany, Ayesha B. M.; Sibeko, Sengeziwe.; Mlisana, Koleka Patience.; Omar, Zaheen.; Gengiah, Tanuja N.; Maarschalk, Silvia.; Arulappan, Natasha.; Mlotshwa, Mukelisiwe.; Morris, Lynn.; Taylor, Douglas. (American Association for the Advancement of Science., 2010-09)
      The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the effectiveness and safety of a 1% vaginal gel formulation of tenofovir, a nucleotide reverse transcriptase inhibitor, for the ...
    • Genital inflammation and the risk of HIV acquisition in women. 

      Masson, Lindi.; Passmore, Jo-Ann S.; Liebenberg, Lenine J.; Werner, Lise.; Baxter, Cheryl.; Arnold, Kelly B.; Williamson, Carolyn.; Little, Francesca.; Mansoor, Leila E.; Naranbhai, Vivek.; Lauffenburger, Douglas A.; Ronacher, Katharina.; Walzl, Gerhard.; Garrett, Nigel.; Williams, Brent L.; Couto-Rodriguez, Mara.; Hornig, Mady.; Lipkin, Walter Ian.; Grobler, Anna Christina.; Abdool Karim, Quarraisha.; Abdool Karim, Salim Safurdeen. (Oxford University Press., 2015)
      Abstract available in pdf.
    • Global epidemiology of HIV-AIDS. 

      Abdool Karim, Salim Safurdeen.; Abdool Karim, Quarraisha.; Gouws, Eleanor.; Baxter, Cheryl. (WB Saunders., 2007-03-01)
      HIV, the cause of AIDS, has in the 25 years since its discovery spread rapidly to every region in the world [1]. To date, more than 65 million people have been infected with HIV and about 25 million people have died ...
    • HIV vaccines and immunity. 

      Abdool Karim, Salim Safurdeen.; Baxter, Cheryl. (Allergy Society of South Africa., 2003-06)
      No abstract available.
    • Improving adolescent maternal health. 

      Baxter, Cheryl.; Moodley, Dhayendre. (South African Medical Association., 2015)
      Abstract available in pdf.
    • Integration of antiretroviral therapy with tuberculosis treatment. 

      Abdool Karim, Salim Safurdeen.; Naidoo, Kogieleum.; Grobler, Anna Christina.; Padayatchi, Nesri.; Baxter, Cheryl.; Gray, Andrew L.; Gengiah, Tanuja N.; Gengiah, Santhanalakshmi.; Naidoo, Anushka.; Jithoo, Niraksha.; Nair, Gonasagrie.; El-Sadr, Wafaa.; Friedland, Gerald H.; Abdool Karim, Quarraisha. (Massachusetts Medical Society., 2011-10-20)
      Background. We previously reported that integrating antiretroviral therapy (ART) with tuberculosis treatment reduces mortality. However, the timing for the initiation of ART during tuberculosis treatment remains ...
    • Microbicides & their implications in HIV prevention. 

      Abdool Karim, Salim Safurdeen.; Baxter, Cheryl. (MedKnow Publications., 2010-12)
      No abstract available.
    • Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies. 

      Abdool Karim, Quarraisha.; Baxter, Cheryl.; Abdool Karim, Salim Safurdeen. (Wiley Online Library., 2014)
      Abstract available in pdf.
    • The need for multipurpose prevention technologies in sub-Saharan Africa. 

      Abdool Karim, Salim Safurdeen.; Baxter, Cheryl.; Frohlich, Janet A.; Abdool Karim, Quarraisha. (Wiley Online Library., 2014)
      Abstract available in pdf.
    • Overview of microbicides for the prevention of human immunodeficiency virus. 

      Abdool Karim, Salim Safurdeen.; Baxter, Cheryl. (Elsevier., 2012)
      Human immunodeficiency virus (HIV) prevention tools that women can use and control are urgently needed. Microbicides are chemical products applied to the vagina or rectum to prevent the sexual transmission of HIV. Four ...
    • Preventing HIV infection in women: A global health imperative. 

      Abdool Karim, Quarraisha.; Sibeko, Sengeziwe.; Baxter, Cheryl. (Oxford University Press on behalf of University of Chicago Press., 2010-05-15)
      Women account for approximately one-half of all human immunodeficiency virus (HIV) infections worldwide. Sexual transmission is the dominant mode of HIV transmission to women, and there is a concomitant associated epidemic ...
    • PRO 2000: next steps for microbicide development. 

      Abdool Karim, Salim Safurdeen.; Baxter, Cheryl. (Future Medicine., 2009)
      No abstract available.
    • Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. 

      Abdool Karim, Quarraisha.; Kharsany, Ayesha B. M.; Frohlich, Janet A.; Baxter, Cheryl.; Yende Zuma, Nonhlanhla.; Mansoor, Leila E.; Mlisana, Koleka Patience.; Maarschalk, Silvia.; Arulappan, Natasha.; Grobler, Anna Christina.; Sibeko, Sengeziwe.; Omar, Zaheen.; Gengiah, Tanuja N.; Mlotshwa, Mukelisiwe.; Samsunder, Natasha.; Abdool Karim, Salim Safurdeen. (Biomed Central, 2011-03-07)
      Background: Young women in sub-Saharan Africa bear a disproportionate burden of HIV infection compared to men but have limited options to reduce their HIV risk. Microbicides could fill an important HIV prevention gap ...
    • Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. 

      Sokal, David C.; Abdool Karim, Quarraisha.; Sibeko, Sengeziwe.; Yende Zuma, Nonhlanhla.; Mansoor, Leila E.; Baxter, Cheryl.; Grobler, Anna Christina.; Frohlich, Janet A.; Kharsany, Ayesha B. M.; Miya, Nomsa.; Mlisana, Koleka Patience.; Maarschalk, Silvia.; Abdool Karim, Salim Safurdeen. (International Medical Press., 2013)
      Background: Tenofovir gel, used vaginally before and after coitus, reduced women’s acquisition of HIV by 39%. This is a safety assessment of tenofovir gel, including renal, bone, gastrointestinal, genital and haematological ...